Journal: Biomedicines

Article Title: Liver-Targeted Nanoparticles Facilitate the Bioavailability and Anti-HBV Efficacy of Baicalin In Vitro and In Vivo

doi: 10.3390/biomedicines10040900

Figure Lengend Snippet: Liver-targeted baicalin liposome (BAA1) and baicalin (BA)-inhibited HBV replication in AAVDJ-transfected HepG2 cells. ( A , B ) AAVDJ-transfected HepG2 cells were treated with ETV (10 μM), BA (25–100 μM), and BAA1 (25–100 μM). HBsAg and HBeAg in the culture supernatants were detected by using ELISA kits. ( C ) HBV-DNA (HBV virion) in the culture supernatants was detected by qPCR. ( D , E ) HBV total RNAs and pgRNA were determined by qRT-PCR. Data are presented as mean ± SD, n = 3; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 vs. control. ns, not significant.

Article Snippet: The HepG2 cells were transfected with AAVDJ vectors [ ] (PackGene Biotech, Guangzhou, China) carrying the HBV genome (genotype B) and called the AAVDJ-transfected HepG2 cells.

Techniques: Transfection, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Control

Journal: Biomolecules

Article Title: Approaches and Vectors for Efficient Cochlear Gene Transfer in Adult Mouse Models.

doi: 10.3390/biom13010038

Figure Lengend Snippet: Figure 2. The AAV delivery approaches make a difference in HC transduction and HC survival in the adult cochlea. The cochleae were harvested 2 weeks after AAV-Anc80L65 was delivered into the adult cochlea (4–6 weeks old). HCs were labeled with Myo7a (red), the nuclei were stained with DAPI (blue), and native eGFP was observed (green). (a,d) Representative high-magnification images of the apex, middle, and base in the AAV-Anc80L65 (1.0 × 1013 VG/mL)-injected ears (a) and contralateral ears (d). (b,c) Quantitative comparison of IHC transduction efficiency (b) and OHC transduction efficiency (c) in injected ears in the four different groups as assessed in 100 µm segments across different regions of the cochlea (apex, middle, and base). (e) Quantitative comparison of IHC transduction efficiency in the contralateral ears in the four different groups, as assessed in 100 µm segments across different regions of the cochlea (apex, middle, and base). (f) Quantification of HCs survival at 2 weeks after AAV-Anc80L65 injection via the different approaches in adult mice, as assessed in 100 µm segments across different regions of the cochlea (apex, middle, and base). Two- way ANOVA with Bonferroni correction was performed for multiple comparisons of transduction rates and survival rates. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: AAV-PHP.eB, AAV-ie, AAV-Anc80L65, AAV2, and AAV-PHP.s were produced by the PackGene Biotech Company (Shanghai, China).

Techniques: Transduction, Labeling, Staining, Injection, Comparison

Journal: Biomolecules

Article Title: Approaches and Vectors for Efficient Cochlear Gene Transfer in Adult Mouse Models.

doi: 10.3390/biom13010038

Figure Lengend Snippet: Figure 3. Cochlear injection of 1 µL AAV-Anc80L65 via PSCC canalostomy in adult mice (4–6 weeks old) does not impair hearing function. ABRs and DPOAEs were recorded at 2 weeks after the injection. (a) ABR waveforms from the representative contralateral ear and the ear injected with 1 µL AAV-Anc80L65 vector through the PSCC approach at 8 kHz. The blue trace indicates the threshold of the contralateral ear while the pink trace indicates the threshold of the injected ear. The scale bar applies to all traces. (f,i) Latencies (f) and peak amplitudes (i) of ABR wave 1 evoked by 90 dB SPL at 4, 8, 16, 24, and 32 kHz in the AAV-Anc80L65-injected ears compared with the contralateral ears 2 weeks after 1 µL PSCC injection. (b–e,g,h,j,k) ABR and DPOAE tests showed no threshold shifts in the 1 µL PSCC group inner ears compared with the contralateral non-injected control ears, whereas the hearing threshold increased at different frequencies to different degrees in the remaining groups. Two-way ANOVA with Bonferroni correction was performed for multiple comparisons for ABR and DPOAE tests. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Article Snippet: AAV-PHP.eB, AAV-ie, AAV-Anc80L65, AAV2, and AAV-PHP.s were produced by the PackGene Biotech Company (Shanghai, China).

Techniques: Injection, Plasmid Preparation, Control

Journal: Biomolecules

Article Title: Approaches and Vectors for Efficient Cochlear Gene Transfer in Adult Mouse Models.

doi: 10.3390/biom13010038

Figure Lengend Snippet: Figure 4. Frozen sagittal brain sections from AAV-Anc80L65-injected adult mice (4–6 weeks old) using different surgical approaches. Two weeks after the cochlear injection, brain tissues were rapidly extracted. The whole sagittal brain section image at the top came from the t-RP group, and the high-magnification images were taken from the following brain regions of each group: the cerebral cortex (1 and 2), midbrain (3), cerebellum (4), and hindbrain (5). The cell nuclei were stained with DAPI (blue), and native eGFP was imaged (green).

Article Snippet: AAV-PHP.eB, AAV-ie, AAV-Anc80L65, AAV2, and AAV-PHP.s were produced by the PackGene Biotech Company (Shanghai, China).

Techniques: Injection, Staining

Journal: International Journal of Molecular Sciences

Article Title: Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays

doi: 10.3390/ijms21124197

Figure Lengend Snippet: rAAV gene therapy products registered on clinicaltrials.gov .

Article Snippet: Over the years, five different AAV- RPE65 products were tested in a total of 13 clinical trials by Applied Genetic Technologies Corporation (AGTC; Alachua, USA), Hadassah Medical Organization (Jerusalem, Israel), Spark Therapeutics (Philadelphia, USA), University of Pennsylvania (Philadelphia, USA), MeiraGTx (London, UK), Nantes University Hospital (Nantes, France), and University College London (London, UK).

Techniques: